TrialBMC cancer2022

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.

Yohei Chiba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.